This company seems to have been delisted
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
Reason: Acquired by AbbVie
Last recorded trade on: April 12, 2024
Source: https://news.abbvie.com/2024-02-12-AbbVie-Completes-Acquisition-of-ImmunoGen
ImmunoGen
IMGN
₹2,677
Share price
0.00%
Change (1 day)
140.71%
Change (1 year)
Categories
ImmunoGen (IMGN) - Total debt
Total debt on the balance sheet as of September 2023 : ₹7.22 Billion
According to ImmunoGen 's latest financial reports the company's total debt is ₹7.22 Billion. A company’s total debt is the sum of all current and non-current debts.
ImmunoGen - Total debt on balance sheet (from 1996 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | ₹1.26 B | -9.76% |
| 2021-12-31 | ₹1.39 B | -19.99% |
| 2020-12-31 | ₹1.74 B | -8.74% |
| 2019-12-31 | ₹1.91 B | 1226.56% |
| 2018-12-31 | ₹0.14 B | 10.26% |
| 2017-12-31 | ₹0.13 B | |
| 2016-06-30 | ₹6.52 B | |
| 2001-06-30 | ₹0.38 M | -97.82% |
| 2000-06-30 | ₹17.53 M | 102.06% |
| 1999-06-30 | ₹8.67 M | 104.2% |
| 1998-06-30 | ₹4.25 M | -40.73% |
| 1997-06-30 | ₹7.16 M | -94.76% |
| 1996-06-30 | ₹0.13 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Seagen
SGEN | ₹9.72 B | 34.57% | 🇺🇸 USA |
 Amgen AMGN | ₹4.918 T | 67,943.40% | 🇺🇸 USA |
 Eli Lilly LLY | ₹3.301 T | 45,572.83% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹4.392 T | 60,660.11% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹4.478 T | 61,861.34% | 🇺🇸 USA |
 Pfizer PFE | ₹5.253 T | 72,579.95% | 🇺🇸 USA |
 Novartis NVS | ₹2.680 T | 36,980.52% | 🇨🇭 Switzerland |
 Sanofi SNY | ₹1.951 T | 26,901.66% | 🇫🇷 France |